美国FDA在今年的3月11日正式批准克唑替尼(Crizotinib,辉瑞)可用于治疗携带ROS-1基因突变的晚期(转移性)非小细胞肺癌(NSCLC)患者。至此,克唑替尼成为目前唯一一个同时获得ALK和ROS-1两个NSCLC治疗性靶点适应性的靶向药物。我们知道,非小细胞肺癌(NSCLC)是目前最常见的肺癌类型,其占肺癌总数的一大半。传统的放化疗治疗方式效果较差,必须根 The FDA officially approved crizotinib (Pfizer) on March 11 this year to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) carrying mutations in the ROS-1 gene. At this point, crizotinib has become the only one that can simultaneously achieve the therapeutic target adaptability of both NSCLCs with ALK and ROS-1. We know that non-small cell lung cancer (NSCLC) is by far the most common type of lung cancer and accounts for more than half of all lung cancers. Traditional radiotherapy and chemotherapy treatment is less effective, must root